2022
Predictive Molecular Biomarkers for HPV-Associated Head and Neck Squamous Cell Carcinoma
Yarbrough W, Schrank T, Blumberg J, Patel S, Hackman T, Lumley C, Burtness B, Issaeva N. Predictive Molecular Biomarkers for HPV-Associated Head and Neck Squamous Cell Carcinoma. International Journal Of Radiation Oncology • Biology • Physics 2022, 112: e17-e18. DOI: 10.1016/j.ijrobp.2021.12.178.Peer-Reviewed Original ResearchNeck squamous cell carcinomaSquamous cell carcinomaNF-kB activityGene expression classifierCell carcinomaPatient outcomesPrognostic biomarkerNF-kBNF-kB pathway genesBetter recurrence-free survivalGoal of physiciansHPV-Associated HeadProgression-free survivalRecurrence-free survivalHigh cure ratesTCGA dataIndependent patient cohortsPredictive molecular biomarkersNF-kB target genesQuality of lifeExpression classifierHNSCC survivorsInduction chemotherapyOPSCC tumorsConcurrent chemoradiation
2021
Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer
Xiao C, Miller AH, Peng G, Levine ME, Conneely KN, Zhao H, Eldridge RC, Wommack EC, Jeon S, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Irwin ML, Ferrucci LM, Ulrich B, Qian DC, Beitler JJ, Bruner DW. Association of Epigenetic Age Acceleration With Risk Factors, Survival, and Quality of Life in Patients With Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2021, 111: 157-167. PMID: 33882281, PMCID: PMC8802868, DOI: 10.1016/j.ijrobp.2021.04.002.Peer-Reviewed Original ResearchConceptsProgression-free survivalBody mass indexQuality of lifeHigher epigenetic age accelerationTreatment-related symptomsOverall survivalEpigenetic age accelerationRadiation therapyRisk factorsClinical characteristicsNeck cancerAge accelerationWorse overall survivalHuman papilloma virusFaster biological agingAdverse eventsDistant metastasisLifestyle factorsMass indexCancer outcomesBlood biomarkersPapilloma virusFunctional assessmentHigher HRPatients
2020
ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer
Cmelak A, Dietrich MS, Li S, Ridner S, Forastiere A, Burtness BA, Cella D, Murphy BA. ECOG-ACRIN 2399: analysis of patient related outcomes after Chemoradiation for locally advanced head and neck Cancer. Cancers Of The Head & Neck 2020, 5: 12. PMID: 33353553, PMCID: PMC7756946, DOI: 10.1186/s41199-020-00059-1.Peer-Reviewed Original ResearchQuality of lifeFunctional communication measuresMajority of patientsVoice Handicap IndexFACT-HNSwallow assessmentEffects of chemoradiationLarge therapeutic trialsPatient related outcomesSevere dysphagiaAdvanced headOverall survivalBarium swallowTherapeutic trialsNeck cancerSwallow functionSurrogate markerDisability AssessmentLarynx cancerFunctional assessmentPatientsHandicap IndexVocal functionRelated outcomesMarked decreaseQuality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040
Harrington KJ, Soulières D, Le Tourneau C, Dinis J, Licitra LF, Ahn MJ, Soria A, Machiels JH, Mach N, Mehra R, Burtness B, Ellison MC, Cheng JD, Chirovsky DR, Swaby RF, Cohen EEW. Quality of Life With Pembrolizumab for Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040. Journal Of The National Cancer Institute 2020, 113: 171-181. PMID: 32407532, PMCID: PMC7850527, DOI: 10.1093/jnci/djaa063.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCetuximabDisease-Free SurvivalDocetaxelHumansMaleMiddle AgedNeoplasm MetastasisNeoplasm Recurrence, LocalPatient Reported Outcome MeasuresQuality of LifeSquamous Cell Carcinoma of Head and NeckConceptsGHS/QoL scoresStandard of careNeck squamous cell carcinomaGlobal health statusSquamous cell carcinomaQOL scoresWeek 15KEYNOTE-040Metastatic HNSCCCell carcinomaNeck cancer-specific modulePlatinum-containing regimenHealth-related qualityCancer-specific moduleQuality of lifeHRQoL benefitsHRQoL populationMetastatic headHRQoL analysisMedian timeLife HeadPembrolizumabPatientsHealth statusEuropean Organization
2017
Biomarker driven treatment of head and neck squamous cell cancer
Eze N, Lo YC, Burtness B. Biomarker driven treatment of head and neck squamous cell cancer. Cancers Of The Head & Neck 2017, 2: 6. PMID: 31093353, PMCID: PMC6460531, DOI: 10.1186/s41199-017-0025-1.Peer-Reviewed Original ResearchNeck squamous cell cancerSquamous cell cancerCell cancerPredictive biomarkersNeck cancerClinical practicePredictive biomarker developmentImmune checkpoint inhibitionPlasma EBV DNATreatment-related toxicityNovel predictive biomarkerNeck cancer therapyTreatment of headCancer therapyImmune checkpoint biomarkersQuality of lifeLong-term functionEBV DNAIndividualized cancer therapyTargeted agentsCheckpoint inhibitionTreatment modalitiesSurrogate biomarkerP16 overexpressionNasopharyngeal carcinomaAssessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies.
Cmelak A, Flamand Y, Li S, Marur S, Murphy B, Cella D, Forastiere A, Burtness B. Assessment of established patient reported outcomes (PROs) instruments measuring toxicities and quality of life (QOL) for patients (pts) with head and neck cancer (HNC) treated on ECOG 1308 and 2399 studies. Journal Of Clinical Oncology 2017, 35: 6074-6074. DOI: 10.1200/jco.2017.35.15_suppl.6074.Peer-Reviewed Original ResearchFACT-HNQuality of lifeLate toxicityConformal RTLow doseHigh cure ratesRT doseTreatment toxicityCure rateStandard doseVanderbilt HeadNeck cancerKatz IndexPatient outcomesInstrumental activitiesOutcome instrumentsDaily livingDose reductionPRO dataIMRT dosePRO instrumentsRT techniquesFatigue indexDosePatientsKEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Shekar T, Brown H, Cheng J, Siu L. KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Journal Of Clinical Oncology 2017, 35: tps6090-tps6090. DOI: 10.1200/jco.2017.35.15_suppl.tps6090.Peer-Reviewed Original ResearchBlinded independent central reviewConcomitant chemoradiotherapyRECIST v1.1LA-HNSCCP16-positive oropharyngeal cancerPrimary efficacy end pointRecurrent/metastatic HNSCCNeck squamous cell carcinomaDefinitive concomitant chemoradiotherapyECOG PS 0Efficacy end pointOutcome of ptsP16 negative HNSCCEvent-free survivalHalf of patientsSquamous cell carcinomaEnd of treatmentIndependent central reviewQuality of lifeMeasurable diseaseAdvanced diseaseCTCAE v4.0Primary surgeryAdvanced headNeck dissection
2014
Targeted agents: management of dermatologic toxicities.
Burtness B. Targeted agents: management of dermatologic toxicities. Journal Of The National Comprehensive Cancer Network 2014, 12: 793-6. PMID: 24853219, DOI: 10.6004/jnccn.2014.0192.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor inhibitorsGrowth factor receptor inhibitorsDermatologic side effectsQuality of lifeDermatologic toxicitiesCutaneous complicationsSkin complicationsTherapeutic mainstayReceptor inhibitorsCommon culpritsToxicity profileMTOR inhibitorsSide effectsCosmetic issuesAnticancer treatmentPotential infectionComplicationsTreatmentInhibitorsTherapyAgentsCancerInfectionMainstayBRAF
2012
ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP).
Marur S, Lee J, Cmelak A, Zhao W, Westra W, Chung C, Gillison M, Gilbert J, Bauman J, Wagner L, Ferris R, Trevarthen D, Colevas A, Jahagirdar B, Burtness B. ECOG 1308: A phase II trial of induction chemotherapy followed by cetuximab with low dose versus standard dose IMRT in patients with HPV-associated resectable squamous cell carcinoma of the oropharynx (OP). Journal Of Clinical Oncology 2012, 30: 5566-5566. DOI: 10.1200/jco.2012.30.15_suppl.5566.Peer-Reviewed Original ResearchOropharyngeal squamous cell carcinomaInduction chemotherapySquamous cell carcinomaQuality of lifeCell carcinomaDay 1Primary siteMedian age 57 yearsResectable squamous cell carcinomaPhase II clinical trialCetuximab loading doseCisplatin 75mg/Pack-years smokingStandard-dose RTTumor stage T1Age 57 yearsHuman papillomavirus infectionPhase II trialProgression-free survivalExpression of biomarkersLow-dose radiationClinical CRRT armTarget accrualToxic regimensInformational needs of head and neck cancer patients
Fang CY, Longacre ML, Manne SL, Ridge JA, Lango MN, Burtness BA. Informational needs of head and neck cancer patients. Health And Technology 2012, 2: 57-62. PMID: 22518350, PMCID: PMC3327509, DOI: 10.1007/s12553-012-0020-9.Peer-Reviewed Original ResearchHNSCC patientsNeck squamous cell carcinomaEarly-stage diseaseMajority of patientsSquamous cell carcinomaConsiderable functional impairmentNeck cancer patientsInformational needsPatients' informational needsQuality of lifeInternet-based programAdvanced diseaseMost patientsYounger patientsMale patientsFemale patientsMajority of participantsCell carcinomaPatient populationCancer patientsTreatment optionsFunctional impairmentPatientsPsychosocial needsEmotional stress